24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
APALIEVA 60 MG is an Tablet medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | APALIEVA 60 MG |
|---|---|
| Composition | Apalutamide Tablets 60 mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Tablet |
| Packaging | Btl (120 tab) |
| Country of Origin | India |
APALIEVA 60 MG (Apalutamide Tablets 60 mg) is a widely used Tablet medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
APALIEVA 60 MG (Apalutamide Tablets 60 mg) is a prescription anticancer medicine containing Apalutamide 60 mg, an oral androgen receptor inhibitor used in the treatment of specific types of prostate cancer. Apalutamide belongs to a class of medicines known as Androgen Receptor (AR) Inhibitors, which help slow the growth and spread of prostate cancer cells by blocking the action of male hormones (androgens).
Prostate cancer cells often rely on androgens, such as testosterone, to grow and multiply. Apalutamide works by binding to androgen receptors, preventing these hormones from activating cancer cells. This helps inhibit cancer cell growth, delay disease progression, and improve treatment outcomes.
APALIEVA 60 MG is commonly prescribed for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). It is generally used in combination with androgen deprivation therapy (ADT) as recommended by an oncologist or urologist.
The medicine is taken orally and should be used only under the supervision of a qualified healthcare professional experienced in cancer treatment.
APALIEVA 60 MG is commonly used for:
Manufactured according to stringent pharmaceutical quality standards, APALIEVA 60 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Apalutamide therapy require regular monitoring of their clinical condition and laboratory parameters to ensure safe and effective treatment.
APALIEVA 60 MG (Apalutamide Tablets 60 mg) is primarily used for the treatment and management of prostate cancer.
Helps delay disease progression in patients whose cancer has become resistant to hormone therapy but has not spread to other parts of the body.
Used in combination with androgen deprivation therapy to improve treatment outcomes.
Supports disease control in patients with advanced stages of prostate cancer.
Blocks androgen receptor activity to slow cancer growth.
Helps reduce the risk of disease progression and supports long-term treatment strategies.
Frequently used with androgen deprivation therapy (ADT) as part of comprehensive prostate cancer treatment.
Apalutamide belongs to a class of medicines known as Androgen Receptor Inhibitors.
APALIEVA works by:
This targeted mechanism helps manage prostate cancer effectively.
Like all medicines, APALIEVA 60 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Weakness and tiredness are among the most frequently reported side effects.
Some patients may develop mild to moderate skin rashes.
Pain or stiffness in the joints may occur.
Blood pressure may increase and should be monitored regularly.
Some individuals may experience a decrease in body weight.
Episodes of warmth and sweating may occur.
Digestive disturbances may develop during treatment.
The medicine may increase the risk of falls or bone fractures in some patients.
Reduced appetite may occur during therapy.
Seek immediate medical attention if you experience:
Patients should contact their healthcare provider immediately if serious symptoms occur.
The dosage of APALIEVA 60 MG (Apalutamide Tablets 60 mg) should always be determined by a qualified oncologist or urologist.
Treatment recommendations depend on the type and stage of the disease.
General health and existing medical conditions may influence treatment.
Organ function may be evaluated before and during therapy.
Other medicines may affect treatment planning due to potential drug interactions.
Dose modifications may be considered based on clinical response and tolerability.
Before starting treatment, inform your doctor if you have:
Patients receiving Apalutamide therapy may require:
Patients should also disclose all prescription medicines, supplements, vitamins, and herbal products they are taking to avoid potential drug interactions.
Women who are pregnant or may become pregnant should avoid handling crushed or broken tablets. Patients should follow their healthcare provider's advice regarding contraception during treatment.
It is used to treat non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC).
Apalutamide is an androgen receptor inhibitor that blocks the effects of male hormones on prostate cancer cells.
No. It is a targeted hormonal therapy, not a traditional chemotherapy medicine.
Yes. It may be taken with or without food, as directed by your doctor.
Yes. Some patients may have an increased risk of falls and fractures, so bone health should be monitored.
Yes. Routine medical evaluations and laboratory monitoring are recommended throughout therapy.
It is generally used in combination with androgen deprivation therapy (ADT), depending on the treatment plan.
Yes. This medicine should only be used under the supervision of a qualified healthcare professional experienced in oncology treatment.